Cortechs.ai, a leader in AI-based neuroimaging and prostate imaging solutions, announced the closing of an oversubscribed Series C funding round led by VILAS Ventures. And existing investor Genting Berhad participated in the round as well.
This funding will fuel the company’s mission to advance medical imaging through cutting-edge technology, expanding its product suite and market reach. The funding round (which exceeded the hard cap by a wide margin) saw strong interest from a diverse group of investors, reflecting high confidence in Cortechs.ai’s innovative solutions.
This funding will accelerate the rollout of new product features, broaden Cortechs.ai’s commercial footprint, and drive ongoing research and development efforts. Built on Professor Anders Dale’s research, Cortechs.ai’s flagship products include NeuroQuant, which plays a critical role in early diagnosis and monitoring of neurodegenerative diseases such as Alzheimer’s, and OnQ Prostate, a fast-growing tool aiding in prostate cancer detection.
Cortechs.ai has been consistently growing by more than 100% while deepening its engagement with current customers and expanding its offering to major healthcare organizations in the US and globally.
Advising Cortechs.ai for this funding round was Chicago-based Uplift Partners.
KEY QUOTES:
“We are thrilled by the enthusiastic response from our investors. This oversubscribed round is a testament to the growing recognition of the critical role our AI-powered tools play in improving diagnostic confidence and patient outcomes. In selecting VILAS Ventures as our capital partner, we valued their deep understanding of healthcare technology, their track record of providing operational support to portfolio companies, and their shared commitment to transforming healthcare. With this support, we’re poised to drive even greater innovation and provide unparalleled value to our clinical partners.”
– Kyle Frye, CEO of Cortechs.ai
“As our inaugural deal, we couldn’t be more thrilled to partner with a visionary company like Cortechs.ai, which has established itself as a frontrunner in AI-driven medical imaging. In our search for the best AI imaging product on the market, Cortechs.ai stood out as a clear leader with the most comprehensive and accurate suite of AI diagnostic tools for the brain and prostate. Their innovation is truly unparalleled, driven by a talented team and a unique ability to bring products to market at record speed. We believe their technology is the leader to address significant gaps in neuroimaging and cancer detection. With this record-breaking investment, we look forward to helping Cortechs.ai realize its extensive product roadmap and continue to expand its position as the global leader in AI diagnostic tools and clinical decision support.”. Livschutz will assume the role of Board Chair, bringing his leadership and expertise to guide Cortechs.ai in this next stage of growth.
– Daniel Livschutz, Managing Director of VILAS Ventures
“Genting has been a proud partner of Cortechs.ai from the very beginning, supporting its journey from research and development to groundbreaking product innovation. We are thrilled to co-invest in this next phase, as the company takes bold steps toward fully realizing its commercial success and transforming patient care through advanced AI-driven imaging solutions.”
– Dato’ Sri Tan Kong Han, COO of Genting Berhad
“It has been an incredible journey founding and building this company, and today, partnering with both Genting Berhad and VILAS truly validates Cortechs’ position as a leader in the neurology and oncology quantitative imaging market. Our innovation continues to advance, with growing demand from clinicians and patients alike for our cutting-edge technology. I am immensely proud of how far we’ve come, and even more excited for the future and the opportunities ahead.”
– Cortechs founder, Anders Dale, PhD
